AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11020745 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol test dose
Number of subjects: 120
Study 11020745 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine or isoproterenol
Number of subjects: 120
Study 9273233 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerodermic children
Number of subjects: 34
Study 9273233 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 34
Study 1510286 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg astemizole
Number of subjects: 12
Study 1510286 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg astemizole
Number of subjects: 12
Study 1510286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6426893 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative enteral feeding via fine bore feeding tube (carbohydrates, fat, short-chain peptides)
Number of subjects: 40
Study 6426893 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous fluids (carbohydrates and amino acids)
Number of subjects: 40
Study 31061014 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (psychosocial intervention administered by speech and language therapists)
Number of subjects: 0
Study 31061014 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 0
Study 28284834 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month active cycling group (ACG, n=33)
Number of subjects: 59
Study 28284834 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=26)
Number of subjects: 59
Study 25886587 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based worker intervention involving home visits and women's group meetings
Number of subjects: 2520
Study 25886587 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving support to Village Health Sanitation and Nutrition Committees only
Number of subjects: 2520
Study 23984830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-acquired medication history
Number of subjects: 270
Study 23984830 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 270
Study 21242364 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive storytelling intervention using 3 DVDs containing patient stories.
Number of subjects: 230
Study 21242364 — intervention group
Group type: COMPARATOR
Intervention: Attention control DVD.
Number of subjects: 230
Study 19602031 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic cardioversion performed within 30 days after recurrence of atrial arrhythmia
Number of subjects: 384
Study 19602031 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic cardioversion performed after recurrence of atrial arrhythmia
Number of subjects: 384
Study 19602031 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to cardioversion within 30 days after onset of atrial arrhythmia
Number of subjects: 384
Study 16882684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine 8% spray
Number of subjects: 25
Study 16882684 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo spray
Number of subjects: 25
Study 15273642 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroform
Number of subjects: 30
Study 15273642 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 30
Study 15273642 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 30
Study 11512528 — intervention group
Group type: EXPERIMENTAL
Intervention: clarithromycin MR 500 mg once daily
Number of subjects: 250
Study 11512528 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin/clavulanic acid 500 mg/125 mg three times daily
Number of subjects: 250
Study 9023466 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 or 50 mg)
Number of subjects: 313
Study 9023466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 8112370 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg oral dose)
Number of subjects: 8
Study 3090845 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 42
Study 3090845 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 42
Study 3090845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anaesthetic techniques
Number of subjects: 42
Study 30048473 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) at 50% of maximal inspiratory pressure for 8 weeks
Number of subjects: 37
Study 30048473 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT) for 8 weeks
Number of subjects: 37
Study 30048473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (CT) for 8 weeks
Number of subjects: 37
Study 30048473 — intervention group
Group type: COMPARATOR
Intervention: Control period (no training) for 8 weeks
Number of subjects: 37
Study 27318221 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐I + P
Number of subjects: 88
Study 27318221 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐I + A
Number of subjects: 88
Study 27318221 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 88
Study 27318221 — intervention group
Group type: COMPARATOR
Intervention: ARM
Number of subjects: 88
Study 27318221 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 88
Study 25186800 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 808
Study 25186800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study 22349455 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0
Study 22349455 — intervention group
Group type: COMPARATOR
Intervention: Wait list control arm
Number of subjects: 0
Study 20644020 — intervention group
Group type: EXPERIMENTAL
Intervention: V(1) ST elevation >or=1 mm
Number of subjects: 7967
Study 20644020 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of V(1) ST elevation >or=1 mm 60 minutes after fibrinolysis
Number of subjects: 7967
Study 20644020 — intervention group
Group type: EXPERIMENTAL
Intervention: V(1) ST elevation analyzed as a continuous variable
Number of subjects: 7967
Study 20644020 — intervention group
Group type: EXPERIMENTAL
Intervention: V(1) ST depression
Number of subjects: 7967
Study 18661769 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (10 mg/kg) along with DTP vaccine
Number of subjects: 270
Study 18661769 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (10 mg/kg) 2 hours after vaccination
Number of subjects: 270
Study 18661769 — intervention group
Group type: COMPARATOR
Intervention: Control group (acetaminophen after febrile reactions or irritability)
Number of subjects: 270
Study 18661769 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 270
Study 16191138 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reminders
Number of subjects: 107
Study 16191138 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer reminders
Number of subjects: 107
Study 16191138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both reminders
Number of subjects: 107
Study 16191138 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 107
Study 12369652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcus vaccination
Number of subjects: 18
Study 12369652 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study 9845865 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient and residential programs
Number of subjects: 2966
Study 9845865 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance programs
Number of subjects: 2966
Study 9845865 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient drug-free programs
Number of subjects: 2966
Study 9845865 — intervention group
Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 2966
Study 9845865 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of dependence diagnosis
Number of subjects: 2966
Study 8591712 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg daily for 12 weeks)
Number of subjects: 20
Study 2612542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam at 0.15 mg.kg‐1
Number of subjects: 56
Study 2612542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal midazolam at 0.15 mg.kg‐1
Number of subjects: 56
Study 2612542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam at 0.15 mg.kg‐1
Number of subjects: 56
Study 2612542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam at 0.45 mg.kg‐1
Number of subjects: 56
Study 2612542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam at 1 mg.kg‐1
Number of subjects: 56
Study 2612542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 56
Study 2612542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 56
Study 2612542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 56
Study 2612542 — intervention group
Group type: EXPERIMENTAL
Intervention: All routes of administration
Number of subjects: 56
Study 1037281 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mefexamide
Number of subjects: 15
Study 1037281 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg mefexamide
Number of subjects: 15
Study 1037281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31622885 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic PRP treatment
Number of subjects: 60
Study 31622885 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 31438858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow mononuclear cells (BMMNCs)
Number of subjects: 0
Study 31438858 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus conventional treatment
Number of subjects: 0
Study 28786105 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 13-cis retinoic acid (7.5 mg or 10 mg) for 2 years
Number of subjects: 176
Study 28786105 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 176
Study 26418022 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 7.5 mg BID
Number of subjects: 12
Study 26418022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23237359 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-containing mouthwash (n = 38; 26% ethanol concentration)
Number of subjects: 107
Study 23237359 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcohol-containing mouthwash (n = 36)
Number of subjects: 107
Study 23237359 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 107
Study 21788309 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB (10 mL every hour beginning 60 minutes after the initial dose)
Number of subjects: 145
Study 21788309 — intervention group
Group type: COMPARATOR
Intervention: CEI (10 mL/h, beginning immediately after the initial dose)
Number of subjects: 145
Study 21788309 — intervention group
Group type: COMPARATOR
Intervention: CEI
Number of subjects: 145
Study 21788309 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB
Number of subjects: 145
Study 21788309 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB and CEI
Number of subjects: 145
Study 19363632 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-shaking maneuver
Number of subjects: 103
Study 19363632 — intervention group
Group type: COMPARATOR
Intervention: Modified Semont maneuver
Number of subjects: 103
Study 19363632 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching maneuvers after initial non-response
Number of subjects: 103
Study 19363632 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastoid oscillation during Brandt-Daroff exercise
Number of subjects: 103
Study 17088770 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-cross-linked hyaluronic acid gel (group A, 30 patients)
Number of subjects: 54
Study 17088770 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B, 24 patients)
Number of subjects: 54
Study 15206994 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs reporting intention-to-treat analysis
Number of subjects: 193
Study 15206994 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs reporting description of withdrawals
Number of subjects: 193
Study 15206994 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs reporting description of adverse events
Number of subjects: 193
Study 15206994 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs reporting ethics review
Number of subjects: 193
Study 15206994 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs reporting informed consent
Number of subjects: 193
Study 15206994 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs reporting sources of funding
Number of subjects: 193
Study 15206994 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs reporting sequence generation
Number of subjects: 193
Study 15206994 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs reporting allocation concealment
Number of subjects: 193
Study 15206994 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs reporting use of restriction
Number of subjects: 193
Study 15206994 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs reporting description of blinding
Number of subjects: 193
Study 15206994 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs reporting flow diagrams of study participants
Number of subjects: 193
Study 10997402 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-times-daily indinavir (800 mg every 8 h or 1200 mg every 12 h) with zidovudine (300 mg) and lamivudine (150 mg) every 12 h
Number of subjects: 521
Study 10997402 — intervention group
Group type: COMPARATOR
Intervention: Two-times-daily indinavir (800 mg every 8 h, 1000 mg every 12 h, or 1200 mg every 12 h) with zidovudine (300 mg) and lamivudine (150 mg) every 12 h
Number of subjects: 521
Study 8769188 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA‐ME (Neoral)
Number of subjects: 22
Study 8769188 — intervention group
Group type: COMPARATOR
Intervention: CyA‐GC
Number of subjects: 22
Study 1591370 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein A perfusion in cancer patients
Number of subjects: 0
Study 1591370 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein A-silica device in immune thrombocytopenia patients
Number of subjects: 0
Study 1591370 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein A perfusion in cancer chemotherapy-related hemolytic-uremic syndrome
Number of subjects: 0
Study 4054140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg TID for 1 week
Number of subjects: 15
Study 4054140 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 1 mg TID for 1 week
Number of subjects: 15
Study 4054140 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 15
Study 30336784 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Timely Appointments for Triage (STAT) model
Number of subjects: 3116
Study 30336784 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 3116
Study 28441294 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial Release (MFR)
Number of subjects: 54
Study 28441294 — intervention group
Group type: COMPARATOR
Intervention: Sham MFR
Number of subjects: 54
Study 26289684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-implemented transitional care (TC)
Number of subjects: 178
Study 23904009 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular treatment (N=15)
Number of subjects: 38
Study 23904009 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (N=13)
Number of subjects: 38
Study 23904009 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N=10)
Number of subjects: 38
Study 21396214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin/clavulanate 30 min before bronchoscopy
Number of subjects: 143
Study 21396214 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 143
Study 18510607 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 17
Study 18510607 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study 16514469 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MR imaging (DWI) for primary acquired cholesteatoma
Number of subjects: 100
Study 16514469 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MR imaging (DWI) for residual cholesteatoma
Number of subjects: 100
Study 14749008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia group (HG); rectal temperature = 34.5 degrees C +/‐ 0.3 degrees C, nasopharyngeal temperature = 34.0 degrees C +/‐ 0.5 degrees C, n = 23
Number of subjects: 50
Study 14749008 — intervention group
Group type: COMPARATOR
Intervention: Normothermia group (NG); rectal temperature = 36.5 degrees C +/‐ 0.5 degrees C, n = 27
Number of subjects: 50
Study 14749008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia group (HG)
Number of subjects: 50
Study 14749008 — intervention group
Group type: COMPARATOR
Intervention: Normothermia group (NG)
Number of subjects: 50
Study 10750548 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation condition (videotape presented)
Number of subjects: 60
Study 10750548 — intervention group
Group type: EXPERIMENTAL
Intervention: No stimulation condition (no videotape)
Number of subjects: 60
Study 10750548 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-hyperactive children)
Number of subjects: 60
Study 8682516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittally symmetric postures
Number of subjects: 10
Study 8682516 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotated body 180 degrees to complete the task
Number of subjects: 10
Study 1499246 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE‐type floss
Number of subjects: 60
Study 1499246 — intervention group
Group type: COMPARATOR
Intervention: Nylon waxed floss
Number of subjects: 60
Study 6150050 — intervention group
Group type: EXPERIMENTAL
Intervention: C6/36 sham vaccine (subcutaneous administration)
Number of subjects: 12
Study 6150050 — intervention group
Group type: EXPERIMENTAL
Intervention: C6/36 sham vaccine (intraderma tests)
Number of subjects: 12
Study 6150050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prausnitz‐Küstner test (using unheated sera)
Number of subjects: 12
Study 6150050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prausnitz‐Küstner test (using heated sera)
Number of subjects: 12
Study 3927959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 120 mg day-1
Number of subjects: 25
Study 3927959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31286497 — intervention group
Group type: EXPERIMENTAL
Intervention: High-status group
Number of subjects: 273
Study 31286497 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-status group
Number of subjects: 273
Study 31286497 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-party context (Study 1)
Number of subjects: 273
Study 31286497 — intervention group
Group type: EXPERIMENTAL
Intervention: Random assignment to high-status or low-status group (Study 2)
Number of subjects: 273
Study 29274727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy (combined aspirin 75 mg, clopidogrel 75 mg, and dipyridamole 200 mg twice daily)
Number of subjects: 3096
Study 29274727 — intervention group
Group type: COMPARATOR
Intervention: Guideline antiplatelet therapy (clopidogrel alone or combined aspirin and dipyridamole)
Number of subjects: 3096
Study 29274727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy
Number of subjects: 3096
Study 29274727 — intervention group
Group type: COMPARATOR
Intervention: Guideline antiplatelet therapy
Number of subjects: 3096
Study 26760400 — intervention group
Group type: EXPERIMENTAL
Intervention: SBAR communication tool implementation
Number of subjects: 72
Study 26760400 — intervention group
Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 72
Study 25676163 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplements
Number of subjects: 332
Study 25676163 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 332
Study 25676163 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 332
Study 23715572 — intervention group
Group type: EXPERIMENTAL
Intervention: AS15 immunostimulant
Number of subjects: 75
Study 23715572 — intervention group
Group type: COMPARATOR
Intervention: AS02B immunostimulant
Number of subjects: 75
Study 20536472 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic thymosin beta4 (Tbeta4) 42-1260 mg, administered intravenously, single dose and daily for 14 days
Number of subjects: 40
Study 20536472 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered intravenously, single dose and daily for 14 days
Number of subjects: 40
Study 18685500 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-free probiotics
Number of subjects: 0
Study 16633359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 40
Study 16633359 — intervention group
Group type: COMPARATOR
Intervention: Normal saline rinses
Number of subjects: 40
Study 14527812 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly men (mean age 67.7)
Number of subjects: 12
Study 14527812 — intervention group
Group type: COMPARATOR
Intervention: Young men (mean age 23.6)
Number of subjects: 12
Study 14527812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 10839287 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPT chemotherapy (dacarbazine, BCNU, cisplatin, and tamoxifen)
Number of subjects: 35
Study 10839287 — intervention group
Group type: COMPARATOR
Intervention: DTIC chemotherapy
Number of subjects: 35
Study 8971427 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (2 x 25 mg day‐1)
Number of subjects: 13
Study 8971427 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (1 x 100 mg day‐1)
Number of subjects: 13
Study 8971427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of captopril and ASA
Number of subjects: 13
Study 8971427 — intervention group
Group type: COMPARATOR
Intervention: Captopril alone
Number of subjects: 13